Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

The only reason I looked into this was

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
JDUR Member Profile
 
Followed By 11
Posts 660
Boards Moderated 0
Alias Born 06/12/13
160x600 placeholder
Amarin jumps after activist Sarissa discloses stake in 13-F filing Seeking Alpha - 11/16/2021 10:52:48 AM
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021 GlobeNewswire Inc. - 11/16/2021 7:00:00 AM
Amarin Reports Subgroup Data from REDUCE-IT® Highlighting Benefits of VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Prior Peripheral Artery Disease (PAD) Presented in Rapid Fire Oral Session Presentation at the American Heart Association Scientific GlobeNewswire Inc. - 11/15/2021 4:30:00 PM
Amarin to Present at Two Upcoming Investor Conferences GlobeNewswire Inc. - 11/11/2021 7:00:00 AM
Latest Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) to be Presented at American Heart Association Scientific Sessions 2021 GlobeNewswire Inc. - 11/8/2021 7:00:00 AM
Amarin shares fall after Q3 topline miss, cash position update Seeking Alpha - 11/3/2021 6:40:19 AM
Amarin EPS beats by $0.01, misses on revenue Seeking Alpha - 11/3/2021 6:03:17 AM
Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 11/3/2021 6:00:00 AM
Amarin Q3 2021 Earnings Preview Seeking Alpha - 11/2/2021 11:36:18 AM
Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021 GlobeNewswire Inc. - 10/20/2021 7:05:00 AM
CEO Presenting on the Emerging Growth Conference on October 13 Register Now InvestorsHub NewsWire - 10/12/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:31:42 AM
Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S. GlobeNewswire Inc. - 9/22/2021 9:15:00 AM
Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany GlobeNewswire Inc. - 9/13/2021 7:00:00 AM
Amarin to Participate in September Investment Conferences GlobeNewswire Inc. - 9/13/2021 6:00:00 AM
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology GlobeNewswire Inc. - 8/31/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 1.  Register Now InvestorsHub NewsWire - 8/30/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 1.  Register Now InvestorsHub NewsWire - 8/30/2021 7:00:00 AM
Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Societ... GlobeNewswire Inc. - 8/23/2021 3:15:00 AM
CEO Presenting on the Emerging Growth Conference on Tomorrow.  Register Now InvestorsHub NewsWire - 8/17/2021 7:00:00 AM
Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiology GlobeNewswire Inc. - 8/16/2021 7:00:00 AM
HLS Therapeutics inks promotional agreement with Pfizer for Vascepa in Canada Seeking Alpha - 8/16/2021 6:55:44 AM
Amarin Q2 Earnings, Revenues Surpass Estimates TipRanks - 8/5/2021 9:58:38 AM
Amarin posts Q2 earnings beat, provides cash position update Seeking Alpha - 8/5/2021 7:58:34 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2021 6:09:55 AM
JDUR   Sunday, 04/05/20 05:00:42 PM
Re: circuitcity post# 262556
Post # of 361622 
The only reason I looked into this was because in the appeal filing they mentioned three items, one of which was the summary judgement. In the summary judgment the only item ruled in favor of the defendant was its usage of non-infringement claims. This was upheld with case precedence citing 5% was enough to establish reasonable usage without infringing. This number rapidly decreases with it's expanded usage.

This gets tricky as the court also held the fact usage can be extended past 12 weeks in the relation to non-infringement usage but didn't take the time to quantify it as the 5% was enough (AMRN expert testimony fuck up) to deem it as a reasonable usage.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences